People · Operator

Georg A. Nebgen, Ph.D.

Named in public records as an officer, director or promoter · Pharmaceuticals

1
Companies
1
Filings
$7.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Kirax CorpPharmaceuticalsSeries A$7.0M$25.6M
Operator network

Georg A. Nebgen, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Joshua A. Kazam · 10 companies · 1 sharedJoshua A. KazamPedro Granadillo · 3 companies · 1 sharedPedro GranadilloEdmundo Muniz, M.D., Ph.D. · 2 companies · 1 sharedEdmundo Muniz, M.…Neil W. Flanzraich · 2 companies · 1 sharedNeil W. FlanzraichAlexander M. Mironov · 1 companies · 1 sharedAlexander M. Miro…Anne White · 1 companies · 1 sharedAnne WhiteBinh Nguyen, M.D., Ph.D. · 1 companies · 1 sharedBinh Nguyen, M.D.…Maninder M. Chopra, Ph.D. · 1 companies · 1 sharedManinder M. Chopr…Mark A. Pruzanski, M.D. · 1 companies · 1 sharedMark A. Pruzanski…Paul A. Mieyal, Ph.D, CFA · 1 companies · 1 sharedPaul A. Mieyal, P…Peter M. Kash, Ed.D. · 1 companies · 1 sharedPeter M. Kash, Ed…Sarita M. Chauhan, Ph.D. · 1 companies · 1 sharedSarita M. Chauhan…Kirax Corp · $7.0M raisedKirax CorpGeorg A. Nebgen, Ph.D.GP
Georg A. Nebgen, Ph.D. Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Georg A. Nebgen, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Joshua A. Kazam110
Pedro Granadillo13
Edmundo Muniz, M.D., Ph.D.12
Neil W. Flanzraich12
Sarita M. Chauhan, Ph.D.11
Alexander M. Mironov11
Peter M. Kash, Ed.D.11
Maninder M. Chopra, Ph.D.11
Binh Nguyen, M.D., Ph.D.11
Mark A. Pruzanski, M.D.11
Anne White11
Paul A. Mieyal, Ph.D, CFA11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.